Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD2 | Q15562 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18011895 | 0.89 | JAK2 (0.44) | TEAD2KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL29654067 | 0.86 | JAK2 (0.51) | TEAD2KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL931470 | 0.86 | JAK2 (0.51) | TEAD2KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL402641 | 0.86 | TEAD2 (0.52) | TEAD2KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL950631 | 0.79 | ALDH1A1 (0.51) | TEAD2KDM4ENPC1RAB9AMAPK1 | |
| SCHEMBL549144 | 0.79 | MAPK1 (0.54) | KDM4EKMT2AMAPK1BAZ2BBAZ2A | |
| SCHEMBL401516 | 0.78 | HTT (0.49) | KDM4ENPC1RAB9AKMT2AMEN1 | |
| SCHEMBL10988922 | 0.77 | MAPK1 (0.63) | TEAD2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL18017492 | 0.77 | CA12 (0.60) | TEAD2KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL15869830 | 0.76 | CHRNA7 (0.47) | KDM4ENPC1RAB9AGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2962566-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2348860-B1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH INC (US) | 2015-05-27 | — | — | EP | disclosed |
| EP-2348860-B1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH INC (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2348860-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010051549-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051549-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | TEAD2 4061/4885KDM4E 1299/4885NPC1 2785/4885 |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | TEAD2 4061/4885KDM4E 1299/4885NPC1 2785/4885 |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | TEAD2 4061/4885KDM4E 1299/4885NPC1 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.